Patents by Inventor Patrick Bernardelli

Patrick Bernardelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110183961
    Abstract: The invention relates to compounds of the formula (I) where: R is a (C1-C6)alkyl group, a halo(C1-C6)alkyl group; R1 is a hydrogen atom; R2 is a heterocyclic group bound by a carbon atom, a heterocyclic-(C1-C4)alkyl group, said groups being optionally substituted; R3 and R4 represent independently from each other an optionally substituted phenyl group; X is a hydrogen atom, a halogen, a cyano, a (C1-C6)alkyl group, a halo(C1-C6)alkyl group, a (C1-C6)alkoxy group, a halo(C1-C6)alkoxy group or a (C1-C6)alkylS(0)p group; and p is 0 to 2. The invention also relates to a method for preparing same and to the therapeutic application thereof.
    Type: Application
    Filed: August 13, 2009
    Publication date: July 28, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Florian Auger, Patrick Bernardelli, Jean-François Sabuco, Corinne Terrier
  • Publication number: 20110152236
    Abstract: The invention relates to compounds of the formula (I) where: R is a (C1-C6)alkyl group, a halo(C1-C6)alkyl group; R1 is a hydrogen atom; R2 is a heteroaromatic group or a heteroaromatic(C1-C4)alkyl group, said groups being optionally substituted; R3 and R4 represent independently from each other an optionally substituted phenyl group; Y is a hydrogen atom, a halogen, a cyano, a (C1-C6)alkyl group, a halo(C1-C6)alkyl group, a (C1-C6)alkoxy group, a halo(C1-C6)alkoxy group or a (C1-C6)alkylS(O)p group; and p is 0 to 2. Said compounds can be in the form— of a base or a salt for addition to an acid. The invention also relates to a method for preparing same and to the therapeutic application thereof.
    Type: Application
    Filed: August 13, 2009
    Publication date: June 23, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Patrick Bernardelli, Jean-Francois Sabuco, Corinne Terrier
  • Publication number: 20110053908
    Abstract: This disclosure relates to compounds of formula (I): wherein R, R1, R2, R3, R4 and Y are as defined in the disclosure, or an acid addition salt thereof, and to processes for the preparation of these compounds and the therapeutic use thereof.
    Type: Application
    Filed: August 26, 2010
    Publication date: March 3, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Florian AUGER, Patrick BERNARDELLI, Luc EVEN, Jean-Francois SABUCO, Corinne TERRIER
  • Patent number: 7851493
    Abstract: The invention relates to phenyl-1,2,4-oxadiazolone derivatives with phenyl group and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What are described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: December 14, 2010
    Assignee: Sanofi-Aventis
    Inventors: Patrick Bernardelli, Stefanie Keil, Matthias Urmann, Hans Matter, Wolfgang Wendler, Maike Glien, Karen Chandross, Lan Lee, Corinne Terrier, Herve Minoux
  • Patent number: 7834030
    Abstract: The present invention comprises phenyl-[1,2,4]-oxadiazol-5-one derivatives of the general formula I: wherein the R1-R10 and B, U, V, W, X, Y and Z substituents are defined herein. The claimed invention also comprises the compounds isomers and their physiologically acceptable salts as well as processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: November 16, 2010
    Assignee: Sanofi-Aventis
    Inventors: Stefanie Keil, Patrick Bernardelli, Matthias Urmann, Hans Matter, Wolfgang Wendler, Maike Glien, Karen Chandross, Lan Lee
  • Patent number: 7709481
    Abstract: The inventive compounds of the present invention are comprised of phenyl and pyridinyl-1,2,4-oxadiazolone derivatives and their physiologically acceptable salts and functional derivatives that are shown to provide peroxisome proliferator activator receptor (PPARdelta) agonist activity. The compounds of the present invention are comprised of the formula: wherein the substituents R1-R5 and R7-R10 are defined herein. The compounds are therapeutically effective in the regulation and modulation of lipid and carbohydrate metabolism in mammals and are thus suitable for the treatment of diseases such as type-2 diabetes, atherosclerosis, cardiovascular disorders and the like.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: May 4, 2010
    Assignee: Sanofi-Aventis
    Inventors: Stefanie Keil, Matthias Urmann, Patrick Bernardelli, Maike Glien, Wolfgang Wendler, Karen Chandross, Lan Lee
  • Patent number: 7709509
    Abstract: The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing peroxisome proliferator activator receptor (PPAR) delta agonist activity comprising compounds of formula I, in which the R1-R7 substituents as well as the U, V, W, X Y and z radicals are as defined herein, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: May 4, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefanie Keil, Wolfgang Wendler, Maike Glien, Jochen Goerlitzer, Karen Chandross, Daniel G. McGarry, Jean Merrill, Patrick Bernardelli, Baptiste Ronan, Corinne Terrier
  • Publication number: 20090281084
    Abstract: The invention relates to phenyl-1,2,4-oxadiazolone derivatives with phenyl group and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What are described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Application
    Filed: May 29, 2009
    Publication date: November 12, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Patrick Bernardelli, Stefanie Keil, Matthias Urmann, Hans Matter, Wolfgang Wendler, Maike Glien, Karen Chandross, Lan Lee, Corinne Terrier, Herve Minoux
  • Patent number: 7576109
    Abstract: The present invention is directed to 1,3,4-oxadiazolones, compounds of formula I and their pharmaceutically acceptable salts stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein. The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: August 18, 2009
    Assignees: Aventis Pharmaceuticals Inc., Sanofi-Aventis Deutschland GmbH
    Inventors: Daniel G. McGarry, Karen Chandross, Jean Merrill, Jochen Goerlitzer, Stefanie Keil, Wolfgang Wendler, Patrick Bernardelli
  • Patent number: 7541464
    Abstract: The present invention relates generally to compounds and compositions for the treatment of metabolic diseases and specifically, the present invention relates to compounds that therapeutically modulation and control lipid and/or carbohydrate metabolism and are thus suitable for the prevention and/or treatment of diseases such as type 2 diabetes, atherosclerosis, and the diverse manifestations thereof. The present invention relates to 7-azaindoles, their physiologically acceptable salts and functional derivatives thereof that exhibit a high degree of peroxisome proliferator-activated receptors (PPAR) agonist activity. Compounds of the present invention are described by formula I: in which the R-groups are herein defined, together with their pharmaceutically acceptable salts, therapeutic methods for their use and processes for their preparation.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: June 2, 2009
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefanie Keil, Maike Glien, Hans-Ludwig Schaefer, Wolfgang Wendler, Patrick Bernardelli, Corinne Terrier, Baptiste Ronan
  • Patent number: 7456164
    Abstract: The invention relates to 3- or 4-monosubstituted phenol and thiophenol derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol and thiophenol derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: November 25, 2008
    Assignee: Pfizer, Inc
    Inventors: Patrick Bernardelli, Andrew Michael Cronin, Alexis Denis, Stephen Martin Denton, Henry Jacobelli, Mark Ian Kemp, Edwige Lorthiois, Fiona Rousseau, Delphine Serradeil-Civit, Fabrice Vergne
  • Publication number: 20080287409
    Abstract: The present invention comprises phenyl and pyridinyl 1,2,4-oxadiazolone compounds their physiologically acceptable salts and physiologically functional derivatives that exhibit peroxisome proliferator activator receptor (PPAR) delta agonist activity. Also described and claimed are processes for their preparation and their use as pharmaceuticals. These are compounds of formula I, in which the R-group substituents are defined herein. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and de-myelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Application
    Filed: March 26, 2008
    Publication date: November 20, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Patrick Bernardelli, Stefanie Keil, Matthias Urmann, Hans Matter, Wolfgang Wendler, Maike Glien, Karen Chandross, Lan Lee, Corinne Terrier, Herve Minoux
  • Publication number: 20080262052
    Abstract: The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or de-myelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.
    Type: Application
    Filed: June 5, 2008
    Publication date: October 23, 2008
    Applicant: SANOFI-AVENTIS Deutschland GmbH
    Inventors: Stefanie KEIL, Wolfgang Wendler, Maike Glien, Jochen Goerlitzer, Karen Chandross, Daniel G. McGarry, Jean Merrill, Patrick Bernardelli, Baptiste Ronan, Corinne Terrier
  • Publication number: 20080262036
    Abstract: The present invention comprises phenyl-[1,2,4]-oxadiazol-5-one derivatives of the general formula I: wherein the R1-R10 and B, U, V, W, X, Y and Z substituents are defined herein. The claimed invention also comprises the compounds isomers and their physiologically acceptable salts as well as processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
    Type: Application
    Filed: March 26, 2008
    Publication date: October 23, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Stefanie Keil, Patrick Bernardelli, Matthias Urmann, Hans Matter, Wolfgang Wendler, Maike Glien, Karen Chandross, Lan Lee
  • Publication number: 20080261979
    Abstract: The inventive compounds of the present invention are comprised of phenyl and pyridinyl-1,2,4-oxadiazolone derivatives and their physiologically acceptable salts and functional derivatives that are shown to provide peroxisome proliferator activator receptor (PPARdelta) agonist activity. The compounds of the present invention are comprised of the formula: wherein the substituents R1-R5 and R7-R10 are defined herein. The compounds are therapeutically effective in the regulation and modulation of lipid and carbohydrate metabolism in mammals and are thus suitable for the treatment of diseases such as type-2 diabetes, atherosclerosis, cardiovascular disorders and the like.
    Type: Application
    Filed: March 26, 2008
    Publication date: October 23, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Stefanie Keil, Matthias Urmann, Patrick Bernardelli, Maike Glien, Wolfgang Wendler, Karen Chandross, Lan Lee
  • Publication number: 20080255212
    Abstract: The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing peroxisome proliferator activator receptor (PPAR) delta agonist activity comprising compounds of formula I, in which the R1-R7 substituents as well as the U, V, W, X Y and z radicals are as defined herein, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or de-myelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.
    Type: Application
    Filed: June 5, 2008
    Publication date: October 16, 2008
    Applicant: SANOFI-AVENTIS Deutschland GmbH
    Inventors: Stefanie KEIL, Wolfgang Wendler, Maike Glien, Jochen Goerlitzer, Karen Chandross, Danie G. McGarry, Jean Merrill, Patrick Bernardelli, Baptiste Ronan, Corinne Terrier
  • Patent number: 7429598
    Abstract: The invention relates to compounds of formula (I) wherein R1, R2 and m are as defined in the description, their use as medicament, pharmaceutical compositions containing them and a process for their preparation.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: September 30, 2008
    Assignee: Warner-Lambert Company
    Inventors: Patrick Bernardelli, Fabrice Vergne, Chrystelle Mendes, Pierre G. Ducrot
  • Publication number: 20070254908
    Abstract: The present invention relates generally to compounds and compositions for the treatment of metabolic diseases and specifically, the present invention relates to compounds that therapeutically modulation and control lipid and/or carbohydrate metabolism and are thus suitable for the prevention and/or treatment of diseases such as type 2 diabetes, atherosclerosis, and the diverse manifestations thereof. The present invention relates to 7-azaindoles, their physiologically acceptable salts and functional derivatives thereof that exhibit a high degree of peroxisome proliferator-activated receptors (PPAR) agonist activity. Compounds of the present invention are described by formula I: in which the R-groups are herein defined, together with their pharmaceutically acceptable salts, therapeutic methods for their use and processes for their preparation.
    Type: Application
    Filed: March 5, 2007
    Publication date: November 1, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Stefanie KEIL, Maike GLIEN, Hans-Ludwig SCHAEFER, Wolfgang WENDLER, Patrick BERNARDELLI, Corinne TERRIER, Baptiste RONAN
  • Publication number: 20070179191
    Abstract: The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or demyelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuroinflammatory processes and/or other peripheral neuropathies.
    Type: Application
    Filed: September 26, 2006
    Publication date: August 2, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Stefanie KEIL, Wolfgang WENDLER, Maike GLIEN, Jochen GOERLITZER, Karen CHANDROSS, Daniel McGARRY, Jean MERRILL, Patrick BERNARDELLI, Baptiste RONAN, Corinne TERRIER
  • Patent number: 7214676
    Abstract: The invention provides compounds which are PDE7 inhibitors, having the following formula (I), (II) and (III) in which X1, X2, X3, X4, X, Y, Z, A and Z1 are as defined in the description, methods for preparing them and their use for the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: May 8, 2007
    Assignee: Warner-Lambert Company LLC
    Inventors: Patrick Bernardelli, Pierre Ducrot, Edwige Lorthiois, Febrice Vergne